Jinyu Bio-technology Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Jinyu Bio-technology kazanç ve gelirin sırasıyla yıllık 43% ve 23.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 41.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

43.0%

Kazanç büyüme oranı

41.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.4%
Gelir büyüme oranı	23.3%
Gelecekteki özkaynak getirisi	7.4%
Analist kapsamı	Low
Son güncelleme	22 Nov 2024

Gelecekteki son büyüme güncellemeleri

Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Sep 02

Recent updates

The Consensus EPS Estimates For Jinyu Bio-technology Co., Ltd. (SHSE:600201) Just Fell Dramatically

Sep 04

Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Sep 02

Why We're Not Concerned Yet About Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) 25% Share Price Plunge

Jun 16

Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Are Reducing Their Forecasts For This Year

Apr 30

There's Reason For Concern Over Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Price

Mar 21

Does This Valuation Of Jinyu Bio-technology Co., Ltd. (SHSE:600201) Imply Investors Are Overpaying?

Feb 28

Kazanç ve Gelir Büyüme Tahminleri

SHSE:600201 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	2,292	505	N/A	651	3
12/31/2025	1,926	388	N/A	445	5
12/31/2024	1,540	283	N/A	468	3
9/30/2024	1,350	165	148	331	N/A
6/30/2024	1,525	272	157	405	N/A
3/31/2024	1,582	283	223	496	N/A
12/31/2023	1,598	284	142	415	N/A
9/30/2023	1,639	289	221	429	N/A
6/30/2023	1,572	240	280	445	N/A
3/31/2023	1,551	236	151	331	N/A
12/31/2022	1,529	211	155	345	N/A
9/30/2022	1,546	174	233	486	N/A
6/30/2022	1,578	229	188	493	N/A
3/31/2022	1,599	252	124	484	N/A
12/31/2021	1,776	382	160	533	N/A
9/30/2021	1,813	529	245	554	N/A
6/30/2021	1,798	482	379	673	N/A
3/31/2021	1,735	467	446	677	N/A
12/31/2020	1,582	406	471	700	N/A
9/30/2020	1,387	268	415	684	N/A
6/30/2020	1,240	234	209	481	N/A
3/31/2020	1,159	213	239	526	N/A
12/31/2019	1,127	221	98	405	N/A
9/30/2019	1,312	322	-13	349	N/A
6/30/2019	1,646	565	-63	408	N/A
3/31/2019	1,673	617	-221	293	N/A
12/31/2018	1,897	754	-123	422	N/A
9/30/2018	2,008	869	196	636	N/A
6/30/2018	1,909	842	N/A	713	N/A
3/31/2018	1,997	900	N/A	840	N/A
12/31/2017	1,901	870	N/A	945	N/A
9/30/2017	1,809	842	N/A	935	N/A
6/30/2017	1,651	748	N/A	910	N/A
3/31/2017	1,635	719	N/A	824	N/A
12/31/2016	1,517	645	N/A	756	N/A
9/30/2016	1,393	561	N/A	764	N/A
6/30/2016	1,309	518	N/A	588	N/A
3/31/2016	1,252	505	N/A	583	N/A
12/31/2015	1,247	480	N/A	494	N/A
9/30/2015	1,210	499	N/A	389	N/A
6/30/2015	1,116	436	N/A	501	N/A
3/31/2015	1,063	433	N/A	460	N/A
12/31/2014	1,063	404	N/A	585	N/A
9/30/2014	921	346	N/A	837	N/A
6/30/2014	874	308	N/A	785	N/A
3/31/2014	849	277	N/A	809	N/A
12/31/2013	671	251	N/A	649	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 600201 'nin tahmini kazanç büyümesi (yıllık 43% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 600201 şirketinin kazançlarının (yıllık 43% ) CN pazarından (yıllık 26.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 600201 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 600201 şirketinin gelirinin (yıllık 23.3% ) CN pazarından (yıllık 13.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 600201 şirketinin gelirinin (yıllık 23.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 600201 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.4 %).

Jinyu Bio-technology Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 17%

Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Price target decreased by 12% to CN¥8.34

Consensus revenue estimates fall by 13%

Price target decreased by 8.9% to CN¥9.38

Price target decreased by 8.0% to CN¥9.48

Recent updates

Jinyu Bio-technology Co., Ltd. (SHSE:600201) announces an Equity Buyback for 15,984,015 shares, representing 1.43% for CNY 160 million.

Jinyu Bio-technology Co., Ltd. (SHSE:600201) announces an Equity Buyback for 15,984,015 shares, representing 1.43% for CNY 160 million.

New minor risk - Profit margin trend

Third quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.14 in 3Q 2023)

Jinyu Bio-technology Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 17%

Consensus revenue estimates fall by 17%

The Consensus EPS Estimates For Jinyu Bio-technology Co., Ltd. (SHSE:600201) Just Fell Dramatically

Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Price target decreased by 12% to CN¥8.34

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Jinyu Bio-technology Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Why We're Not Concerned Yet About Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) 25% Share Price Plunge

Investor sentiment deteriorates as stock falls 20%

Now 20% overvalued after recent price rise

New minor risk - Shareholder dilution

Jinyu Bio-technology Co., Ltd., Annual General Meeting, May 27, 2024

Consensus revenue estimates fall by 13%

Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Are Reducing Their Forecasts For This Year

Price target decreased by 8.9% to CN¥9.38

Jinyu Bio-technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Price target decreased by 8.0% to CN¥9.48

There's Reason For Concern Over Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Price

Does This Valuation Of Jinyu Bio-technology Co., Ltd. (SHSE:600201) Imply Investors Are Overpaying?

Now 20% overvalued

Now 26% overvalued

Investor sentiment deteriorates as stock falls 17%

Jinyu Bio-technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 10% to CN¥10.33

Second quarter 2023 earnings released: EPS: CN¥0.024 (vs CN¥0.02 in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 1Q 2022)

Price target increased by 8.4% to CN¥11.82

Jinyu Bio-technology Co., Ltd. announced that it expects to receive CNY 799.999997 million in funding from Inner Mongolia Jinyu Biological Holdings Co., Ltd., and other investors

Price target increased to CN¥11.87

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.14 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.041 in 2Q 2021)

Consensus revenue estimates fall by 20%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Jinyu Bio-technology Co., Ltd. (SHSE:600201) announces an Equity Buyback for CNY 300 million worth of its shares.

Price target decreased to CN¥22.80

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.041 (vs CN¥0.028 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.13 in 1Q 2020)

New 90-day low: CN¥20.00

New 90-day low: CN¥21.54

New 90-day low: CN¥22.60

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations, earnings disappoint

New 90-day low: CN¥23.40

Jinyu Bio-technology Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

Price target raised to CN¥30.56

Earnings released

Jinyu Bio-technology Co., Ltd. to Report First Half, 2020 Results on Aug 15, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin